BRACAnalysis® Large Rearrangement Test (BART)

Comprehensive BRACAnalysis® is a highly reliable and accurate test that includes complete sequencing of the BRCA1 and BRCA2 genes and an additional procedure to identify five common large rearrangements in the BRCA1 gene. The BRACAnalysis Large Rearrangement Test (BART) was launched to provide a way to detect additional large genomic rearrangements in both BRCA1 and BRCA2. Although each patient must be evaluated individually based on his or her personal and family history, there is, on average, a less than 1% chance that BART will identify a mutation in a patient who has already had a negative result from Comprehensive BRACAnalysis. Additional BART Resources: Integrated BRACAnalysis® to include BART BART Prevalence Table and FAQ  BART Customer Letter BART Medicare Coverage Clinical Summary - Clinical Significance of Large Rearrangements in BRCA1 and BRCA2  

BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions